Remimazolam is a newly introduced intravenous anesthetic, with rapid onset and offset. Although it is known to cause less hemodynamic instability, the incidence hypotension is the one of the most frequent adverse events with its use. For anesthetic induction, remimazolam can be used either as bolus dose or as continuous infusion.

This study is aimed to investigate the incidence of hypotension after anesthetic induction with bolus (0.14-0.33 mg/kg) or continuous (12 mg/kg/hr) remimazolam administration.

Inclusion Criteria:

• scheduled for elective surgery under general anesthesia
• adult patient (over 19 years old)
• American Society of Anesthesiology Physical Status I-III

Exclusion Criteria:

• arrythmia
• liver dysfunction
• kidney dysfunction
• uncontrolled hypertension
• uncontrolled diabetes mellitus
• allergic to benzodiazepines
• heart failure
• drug intoxication
• alcohol intoxication